Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

377
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
377
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

380
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
380
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

703
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
703
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

209
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
209
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

454
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
454
Drug Therapy01:28

Drug Therapy

97
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
97

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Apathy in Parkinson's Disease: Distinguishing Overlapping Symptoms Via Network Analysis.

Movement disorders clinical practice·2026
Same author

True vignettes: interesting, illustrative examples of behavioral abnormalities in people with Parkinson's disease.

Arquivos de neuro-psiquiatria·2026
Same author

Cognitive Fluctuations, Neuropsychiatric Burden, and Quality of Life in Moderate-Advanced Dementia With Lewy Bodies: The Role of Dysautonomia.

Neurology·2026
Same author

Perspective: Depression in Persons with Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Early Autonomic Burden in Prodromal Parkinson's Disease Predicts Cognitive Impairment.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

A Holistic Wellness Prescription for Parkinson's Disease: Evidence-Based Perspectives and Unmet Needs.

Movement disorders clinical practice·2025

Related Experiment Video

Updated: Sep 10, 2025

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.5K

Do we need drugs for psychiatric symptoms specifically for Parkinson's disease?

Kelly A Mills1, Gregory M Pontone2,3

  • 1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Journal of Parkinson'S Disease
|August 21, 2025
PubMed
Summary

Developing new medications for psychiatric symptoms in people with Parkinson's disease (PD) requires further attention to treatment targets. This review examines current pharmacologic treatments and proposes future directions for improved therapies.

Keywords:
Parkinson's diseaseanxietyapathydepressionimpulse controlpsychosis

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.9K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.1K

Related Experiment Videos

Last Updated: Sep 10, 2025

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.5K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.9K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.1K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Psychiatric symptoms are highly prevalent in people with Parkinson's disease (PWP), often appearing in the prodromal phase.
  • These symptoms are intricately linked with motor impairments and their treatments, suggesting potential mechanistic connections.

Purpose of the Study:

  • To review existing pharmacologic treatments for psychiatric symptoms in PWP.
  • To explore future strategies and targets for developing novel medications for psychiatric symptoms in PD.

Main Methods:

  • Literature review of current evidence for pharmacologic treatments.
  • Exploration of potential mechanistic links between psychiatric and motor symptoms.

Main Results:

  • Current pharmacologic treatments for psychiatric symptoms in PWP are discussed.
  • The complex interplay between psychiatric symptoms, motor symptoms, and treatments is highlighted.

Conclusions:

  • Further research into the mechanistic connections is needed.
  • Novel therapeutic targets and approaches are essential for developing effective medications for psychiatric symptoms in Parkinson's disease.